HistoIndex AI Analysis Confirms Strong Fibrosis Improvement in D&D Pharmatech’s Phase 2 MASH Trial This month, HistoIndex announced new data highlighting the value of AI-powered quantitative pathology in advancing MASH drug development. Using our  proprietary  AI algorithm, qFibrosis®, we conducted an independent analysis of liver biopsies from D&D Pharmatech’s Phase 2 trial of zabopegdutide (DD01) – […]

April Highlights Driving Momentum Through New Strategic  Partnerships in Texas and California The past month, we continued to build momentum, expanding access to advanced quantitative diagnostics across the U.S. through new partnerships with Houston Research Institute (HRI) Kingwood in Texas and Knowledge Research Center (KRC) in Orange, California.  HRI Kingwood is a new addition to

March Highlights qFibrosis® Revealing New Insights into Treatment Response with Resmetirom in the MAESTRO-NASH Phase 3 Study qFibrosis® once again takes center stage in advancing our understanding of fibrosis in MASH.  A recent Journal of Hepatology publication, “Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH Phase III clinical trial,” highlights how

February Highlights qFibrosis® Uncovers Divergent Collagen Remodeling Across Liver Disease Subtypes A recent study conducted by Seoul National University Boramae Medical Center and Kyung Hee University Hospital provides new insights into fibrosis progression across steatotic liver disease subtypes. Now published in Gastroenterology, the study utilized HistoIndex’s fibrosis quantification algorithm, qFibrosis®, to identify distinct patterns of

Advancing MASH Diagnostics Through Strategic Partnerships January 20, 2026 – HistoIndex is set to expand its footprint in clinical hepatology and gastroenterology through new commercial partnerships with leading medical centers in the US and Europe. These collaborations unlock our unique diagnostic offering, which combines standard histopathological evaluation by expert pathologists with AI-driven biopsy analysis. Such